Figure 6.

Preventive treatment with OM–85 modulates lymphocytes and lymphoid cell types in the lung in response to RSV infection. Mice were treated intranasally with OM–85 (1mg) 5 days prior to RSV infection (four OM–85 delivery). Afterwards, mice were infected with RSV (1x10⁷ PFU/ml) and received another OM–85 boost 6h later. BAL and lungs were harvested at day 5 post–infection. (A, B) Percentage of CD3⁺CD4⁺IFNγ⁺ Th1 cells in the lung and its representative FACS profile. (C, D) Percentage of CD45⁺CD3⁺CD4⁺IL–4⁺ Th2 cells in the lung and its representative FACS profile. (E, F) Percentage of CD45⁺CD4⁺CD25⁺FoxP3⁺ Treg cells in the lung and its representative FACS profile. (G, H) Percentage of Lineage^–CD45⁺CD90.2⁺ST2⁺Gata3⁺ ILC2 cells in the lung and its representative FACS profile. All data are expressed as mean ± SEM. Multiple groups were compared using Kruskal–Wallis. *p < 0.05. **p < 0.01.